UK Launch Of Astra's MUSE

Astra Pharmaceuticals has launched its transurethral product for thetreatment of male erectile dysfunction of primarily organic etiology, MUSE (alprostadil), a synthetic form of the vasodilator prostaglandin E1, in the UK. It was launched in its first market, the USA, in January last year.

A Phase III clinical trial of MUSE, which is licensed from VIVUS Pharmaceuticals, demonstrated that it was effective in 65.9% of patients in the clinic, while 64.9% of men in the home treatment phase achieved intercourse at least once versus 18.6% of placebo receivers.